Hepatitis E: Current Status in India and Other Asian Countries

Harsh Kumar¹, Nassim Kamar² and Dinesh Kumar¹*

¹School of Bioengineering & Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan - 173 229, H. P., India. ²Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, INSERM U1043, IFR –BMT, University Paul Sabatier, Toulouse, France.

Abstract

Six types of hepatitis infections are accounted for the inflammation of liver in human throughout the world and assigned the letter A, B, C, D, E and G. Out of these, Hepatitis E, caused by Hepatitis E virus (HEV), currently categorized as a member of the genus Hepevirus in the family Hepeviridae. Hepatitis E is considered highly significant, on account of its predominance in both developed and developing nations, due to poor sanitation and cleanliness condition related to drinking water. This review focuses on general epidemiological study update of hepatitis E virus in India and rest of Asia for the selected period and also throws light on some diagnostic approaches available for the same. An extensive literature search was performed with published work and search in PubMed using term “HEV” combined with “country name” restricting the search publication between year 2008 to 2018 for India and 2013 to 2018 for the rest of Asia. The data was analyzed in detail to meet the requirements of the objectives. Study showed that in India the major causes of Hepatitis E was water contaminated with fecal matter. Reports from East and Southeast Asia signified the role of animal reservoir especially the pigs for HEV. Whereas in Indian neighboring countries like Nepal, Pakistan and Western Asia the major cases of Hepatitis E were associated with blood transfusion and pregnancy related cases. Majority of the diagnostic approaches used in India at medical facilities are based on anti-HEV IgM detection. However, the molecular based approaches played very crucial role in HEV detection. It is observed that the incidence of HEV is gradually expanding and its objective range is not only just developing countries, but also showing an enhancement. In overall, there is need for improvements in detection of HEV disease and methodologies used for the development of HEV vaccines.

Keywords: Hepatitis E; Hepatitis E virus; anti-HEV antibodies; Seroprevalence.
INTRODUCTION

Hepatitis is an augmentation of the liver; a condition that can act naturally restrictant or can lead to cirrhosis, fibrosis (scarring), or liver cancer. Researchers have recognized 6 types of hepatitis infections, distinguished by the letters A, B, C, D, E, and G. Hepatitis A virus (HAV) was first perceived in 1947 in worldwide yet is exceptionally common in the developing nations and Greenland and further, its worldwide occurrence is diminishing as a direct result of enhanced clean and living conditions. Hepatitis B virus (HBV) is usually transmitted via exposure of contaminated semen, blood, and other body fluids. Hepatitis C virus (HCV) is mostly transmitted due to exposure to infective blood, transfusions of HCV-tainted blood and blood items. Hepatitis D virus or delta virus, is a defective RNA virus that can replicate itself, still it requires simultaneous HBV for assembly and discharge; accordingly, patients with HDV in every case are dually infected with HBV. The hepatitis G virus (HGV) is again a blood-borne virus spread via blood, and other body fluids. Hepatitis E virus (HEV), similar to HAV, is transmitted through utilization of debased food and water, and its pervasiveness is regular in both developing and developed countries.

An enteric transmitted non-A, non-B hepatitis virus was first reported in view of epidemiological examinations during a flare-up of viral hepatitis in 1978-1979 in Kashmir locale. Soon after the fact, serological testing of sera was done after an extensive episode of hepatitis in New Delhi amid 1955-1956 and two reports in Ahmadabad (1975-1976) and, Pune (1978-1979) in India. Samples from none of the three episodes demonstrated confirmation of acute hepatitis A and just few reports showed markers of acute hepatitis B, thus providing important help in confirmation of an enteric non-A, and non-B hepatitis. The non-A, and non-B hepatitis virus was also found after an episode of mysterious hepatitis in Soviet military in Afghanistan. A member of research team ingested a pooled fecal extract from affected military personnel, and finally suffered with acute hepatitis and small viral particles were identified in his stool through immune electron microscopy. The term hepatitis E virus (HEV) was coined, in view of its enteric transmission and relationship with hepatitis scourges. Currently HEV is classified as a member of genus Hepeivirus in the family Hepeviridae. This review focuses on general epidemiological study update of HEV in India and rest of Asia for the selected period and also throws light on diagnostic approaches available for the same. For this study, keyword literature search was performed in PubMed using term “HEV” combined with “country name” restricting the search publication between year 2008 to 2018 for India and 2013 to 2018 for the rest of Asia. Any article that has been published between 2008 and 2018, but, in which sampling data was taken before 2008, has not been included. Similarly for rest Asia, in which sampling data was taken before 2013, has not been included.

Molecular Biology and Classification of HEV

HEV is a non-enveloped virus, with an icosahedral capsid of 27-34 nm size. The virus possesses a single-stranded, positive-sense, 7.2-kb RNA genome showing capping and polyadenylation at the 5′ and 3′ ends, individually. The HEV genome has three open reading frames (ORFs) as shown in figure 1. ORF1 encodes a protein of 1,693 amino acids comprising functional domains itself present in the nonstructural proteins of other positive-strand RNA viruses. These functional domains contain cysteine protease, methyltransferase, RNA helicase, and RNA-dependent RNA polymerase areas. ORF2 encodes 660 amino acids, a viral capsid protein responsible for virion assembly, immunogenicity, and interaction with target cells. The ORF2 protein having three linear domains: the shell domain (S) (amino acids 129 to 319), the center domain (M) (amino acids 320 to 455), and the protruding domain (P) (amino acids 456 to 606) harboring the neutralizing epitope(s) of the neutralizing epitope(s). ORF3, which overlaps ORF2, encodes a small protein of 113 or 114 amino acids, is associated with virion morphogenesis and discharge. The HEV genomes of a few topographically distinctive isolates demonstrate a high level of sequence conservation. Four phylogenetically unique genotypes have been characterized, which disseminate by geographic regions. In Asian and African regions HEV strains belonging to genotype 1 was more prevalent, genotype 2 incorporates the single Mexican HEV strain and few of variants identified as endemic in African nations. In industrialized nations genotype 3 with human and...
swine HEV strains are common, whereas in East Asia especially China, Taiwan and Japan, genotype 4 incorporates swine HEV and human strains. The avian HEV was proposed to exhibit a place with another genotype, but this has not yet been affirmed.

HEV in India from 2008-2018

At first the epidemics of acute hepatitis E, transmitted by means of polluted water, were reported in developing nations including India. Now the examples have changed with pace of time; and water-borne fecal-oral transmission is unable to justify the locally-acquired cases of hepatitis E in developed countries, as sterile and clean conditions have improved a lot. In such nations, now the zoonotic transmission via ingestion of uncooked meat has been considered to be the principle cause of HEV infection. Defiled water is still considered the prime suspect for spread of hepatitis E (Table 1) although there are also some reports based on transfusion-mediated HEV transmissions. In 2011, a flare-up of water linked hepatitis in Bathinda city, Punjab, showed the presence of 64.19% cases of HEV in the blood tests of the patients. Study showed that the poverty and lack sanitation is firmly related with HEV infection. Blood tests reports gathered from the patients, in Nanital, Uttarakhand revealed the presence of high rate of HEV in drinking water due to sewage tainting of drinking water supply. Two suburban (Nawanshahar and Palsora) of Punjab were suspected with the viral hepatitis episode related with sewage defilement of drinking water. Another research in similar zones, compared the acute viral hepatitis patients (AVH) along with healthy and subclinical subjects (apparently healthy) and observed that both the strains were having a common source of infection, but with low viral load. Another research also reported the flare-up of HEV in Northwest region of Punjab with fecal contamination of drinking water among 21-30 years of age group. Vertical transmission of HEV contaminations at the rate of 78.9% (based on IgM, IgG anti-HEV and HEV RNA positive) was confirmed in newly conceived babies. The biochemical, clinical, serological and virological profile of survived children showed that HEV contamination (mother-to-fetus transmission) in neonates is a self-restricting disease and does not cause unending viremia or delayed clinical course. Dual infection of hepatitis E and B was accounted in Delhi for first time, and 26 patients with double infections showed that hepatitis B virus (HBV) infected chronic carriers patients were secondarily infected with HEV and resulted in acute hepatitis. A report from Ahmadabad, Gujarat showed 4.78% HEV cases among the blood donors. The age of the study group ranged from 18 to 60 years and age of 41-60 years tended to have higher HEV seroprevalence rates of 10.34% (positive IgM anti-HEV). In general less seroprevalence among blood donors is connected with proper sanitation facilities in their respective areas and to some extent the social status. Anti-HEV IgG rate was 60.5% among the blood donors in the range of 18 and 63 years in Lucknow and showed comparable anti-HEV rates among male and female. A hospital-based investigation in West Bengal, revealed the detection of anti-HEV IgG in 41.8% AVH patients and 23% in healthy people. The high prevalence of anti-HEV IgG in healthy control shows the presence of subclinical infection. Another hospital-based investigation showed that low HEV prevalence in kids (9.79%) may be related with improvement in living standards of the population. HEV antigen measure can be used as an extra analytic marker to show the viral replication in HEV infection. HEV strains isolated from sewage samples collected from Vellore belonged to genotype 1 and have shown 94-100% sequence similarity with HEV strains have isolated earlier from acute hepatitis E cases at Vellore hospital. An examination report from Punjab has shown pigs as a reservoir of HEV with 65.0% rate and high seropositivity (18.70%) in developing pigs. A study in Lucknow medical hospital reported the presence of anti-HEV IgG and IgM in the renal transplant patients, however all the results were negative for HEV RNA and the finding suggested the infrequent nature of chronic infection with genotype 1 HEV.

Integrated Disease Surveillance Programme (IDSP)

As per IDSP, India report (2018), from 2013 to 2018 an aggregate of 22671 cases of HEV have been reported and out of these 152 deaths were reported. Similarly, 1667 cases of suspected hepatitis have additionally been reported with 1 death case as shown in Table 2. In all the cases, polluted drinking water with fecal containment
Table 1. Prevalence of Hepatitis E Virus (HEV) cases in India from 2008-2018

| Region of HEV Occurrence | Study Period | Study Population | Sample Size | Source of Sample | Detection of Anti-HEV Antibodies (%) | Detection of HEV RNA (%) | References |
|--------------------------|--------------|------------------|-------------|------------------|-------------------------------------|-------------------------|------------|
| Srinagar                 | NS           | New Born Babies AVH patients* | 19          | Blood Serum      | IgM (63.15), IgG (15.78), IgM (32.16) | RNA (52.63)         | 34         |
| New Delhi                | 1 year       | AVH patients*     | 1141        | Blood Serum      | IgM (64.19), ND                       | ND                      | 35         |
| Bathinda                 | 2011         | AVH patients*     | 81          | Blood Serum      | IgM (17.97), ND                       | ND                      | 29         |
| Lucknow                  | 2011-2012    | AVH patients*     | 267         | Blood Serum      | IgM (78.51), RNA                      | RNA (35.71)           | 38         |
| New Delhi                | 2010-2012    | AVH patients*     | 156         | Blood Serum Sewage| ND                                    | RNA (55.6)            | 39         |
| Vellore                  | 2009-2010    |                       | 144         | Blood Serum      | IgM (35.04), IgG (43.58), IgM (4.78) | ND                      | 40         |
| Kolkata                  | 2012-2013    | AVH patients* Blood donors | 285         | Blood Serum      | IgM (76.92), ND                       | ND                      | 37         |
| Ahmadabad                | August - December 2012 | AVH patients* | 460         | Blood Serum      | IgM (61.9)**, IgG (43.58), IgM (4.78) | ND                      | 36         |
| Nainital                 | January- March 2012 | AVH patients* Healthy Persons Icteric Patients | 240         | Blood Serum      | IgM (86.66)**, IgG (47.61)** | RNA (30.0)** | 31         |
| Pulsera and Nawasahar    | March- April 2012 | IgM (68.42) | 67 | Blood Serum      | RNA (0.27) ND | ND                      | 33         |
| Ludhiana                 | NS           | Pigs Healthy Humans | 320         | Serum Stool      | IgG (60.48) ND | ND                      | 41         |
| Amritsar                 | 2015-2016    | AVH patients* Blood donors | 95          | Blood Serum      | IgM (68.42), IgG (60.5) ND | ND                      | 33         |
| Lucknow                  | June-July 2016, November-December 2016 | Kidney transplant patients | 205         | Blood Serum      | IgG (25.3), IgM (6.8) ND | ND                      | 42         |

NA (Not Specified); ND (Not Determined)

*Acute Viral Hepatitis; **Two cities collective; ***Nawasahar samples only

was the primary reason for flare-ups and anti-HEV IgM was well distinguished in patients’ blood serum.

HEV in Asia from 2013-2018

Different epidemiological studies carried out by the researchers in Asia from year 2013 up to 2018 have been documented in Table 3 and discussed in the following sections: Cases Related to Animals and Animal Foods

Zoonotic transmission through direct
contact or food items from the infected animals have mostly accounted for HEV infections in human beings. In China, several cases of HEV in the form of HEV RNA and Anti-HEV antibodies have been reported in animal food products. In rodents shrews, a rate of HEV 1.66% was observed and phylogenetic analysis revealed 84.7% of nucleotide sequence similarity with hepatitis E virus (rat/R63/DEU/2009) in Germany and 84.9% sequence similarity with HEV isolate (Vietnam-105) with rats in Vietnam. Three HEV strains isolated from the wild rats in one of the Chinese city indicated nucleotide sequence having 88.9-94.3% and 93.4-94.3% similarity respectively with Vietnamese rats and HEV strain V-105. This study also highlighted the possibility of transmission of HEV between rats as fecal-oral route in these similar to human HEV. From 17 mammal species an aggregate of 822 fecal samples and from 24 avian species 67 fecal samples were examined for the presence of HEV in other region of China, and apart from swine and rabbits none of the mammalian species showed presence of HEV RNA. A high positive rate of HEV RNA in swine, made swine as important reservoir for HEV, and, nucleotide sequence similarity of 98% with genotype 4 affirmed the event of HEV transmission from swine to people. On the other hand, avian HEV RNA was detected from sick (with dual infection of HEV and Marek’s disease virus) and healthy chickens; and all three HEV strains indicated 95.5%-97.9% group similarity with chicken from Europe and different parts of China. Research conducted on pigs in Tibet demonstrated that the female pigs had 1.4 times higher danger of acquiring infection when contrasted with male pigs and additionally pigs with age >1 year had 2 times higher danger of being positive. Comparative examination of Tibetan pigs and isolated HEV strains showed similarity with genotype 4. HEV strains isolated from goat showed similarity with genotype 4 and shared 99.9%-99.8% homology with swine HEV strains and also showed 99.6%-99.7% similarity to human HEV and share 99.6%-99.7% likeness to cow HEV, thus showing cross-species transmission. Another investigation on goat, exhibited 2 HEV strains belonging to genotype 4 and showing sequence similarity with cows, humans and pigs. Blood sera gathered from sheep and sheep butchers in China showed 35.2% anti-HEV antibody in sheep blood, 57.7% in butcher’s blood, and among sheep the most elevated cases were among adult in contrast with young ones and all the isolates belonged to genotype 4. Study was done in HEV patients and different food items in Hong Kong and all HEV patients had 100% IgM anti-HEV and 82% of HEV RNA from pig liver, intestine and oysters. Experts from Japan have shown the presence of HEV in wild boars in few territories and phylogenetic tree examination showed that the majority of the HEV strains resembled with genotype 3. Another report from Japan found the highest positivity of HEV RNA among 3-months old pigs. HEV was also additionally found in Japanese bats and BLAST study showed the highest sequence similarity with German strain. Although, the research only commented on the geographical distribution of BatHEV among different bat species; yet it failed to connect the presence of same HEV strains in Japanese and German bats. In South Korea, fecal sample of the pigs were gathered from 14 farms in which 5 farms contained HEV-3, while other 2 had HEV-4 only. HEV RNA detected from rabbit’s feces in Korea is arranged into rabbit clad within HEV-3 and one of the rabbit HEV isolate was named as KOR-RB-1. The full length genome of such isolate showed 86.8%, 86.6% and 80.2-84.3% nucleotide similarity with rabbit HEV strains in China, USA and France respectively. HEV from specific-pathogen free (SPF) rabbits purchased from the local sellers in Korea, showed 86.1-86.8%, 82.4-85.7%, and 86.4-89.7% similarities respectively with rabbit HEV isolated from USA, France and China. A

**Table 2.** Hepatitis E cases in India from 2013-2018 based on Hospital findings

| Year | No. of Cases Reported | No. of Deaths | Suspected Cases | No. of Deaths |
|------|----------------------|---------------|----------------|---------------|
| 2013 | 1153                 | 1             | 400            | 0             |
| 2014 | 1097                 | 12            | 746            | 0             |
| 2015 | 4460                 | 26            | 145            | 0             |
| 2016 | 13997                | 112           | 90             | 0             |
| 2017 | 1611                 | 1             | 120            | 1             |
| 2018’| 353                  | 0             | 166            | 0             |

*upto 33rd Week, data has been included.
Complied from source: [http://www.idsp.nic.in](http://www.idsp.nic.in)
### Table 3. Prevalence of Hepatitis E Virus (HEV) cases in Asia from 2013-2018

| Asian Parts | Region of HEV Occurrence | Study Period | Study Population | Sample Size | Source of Sample | Detection of Anti-HEV | Detection of HEV RNA (%) | Antibodies (%) | References |
|-------------|--------------------------|--------------|------------------|-------------|------------------|-----------------------|--------------------------|----------------|------------|
| China       | December 2011-September 2012 | Wild Rats | 713 Blood | IgG (23.3), Serum | RNA (1.68) | IgM (8.3%) | 45 |
| China       | NS                       | Healthy Persons | 1638 Blood Serum | IgG (12.03), IgM (1.89) | RNA (0.6) | 73 |
| China       | January-February 2014 | Healthy Sheep | 575 Blood Serum | Anti-HEV antibody (35.2) | ND | 52 |
| China       | 2013-2014 | Healthy Men | 26 Blood Serum | Anti-HEV antibody (57.7) | ND | RNA(5.33) |
| China       | NS | Mammal Species | 822 Fecal | ND | Both IgG and IgM (2.93) | RNA (33.0, 30.0, 92.0) | ND |
| China       | NS | Avian Species | 24 Fecal | ND | RNA (80.0) | 47 |
| China       | East | Healthy Chickens | 5 Liver | ND | RNA (56.0%) | 46 |
| China       | East | Chickens with MD and HEV Chronic | 1 Urine | ND | RNA (100.0) | 88 |
| China       | NS | Healthy Persons | 8 Urine Blood Serum | IgG (22.20) | RNA (37.5) | ND |
| China       | NS | AVH patients | 62 Blood Serum Fecal | IgG (76.0), IgM (100) | ND | RNA (58.0) | 101 |
| China       | NS | Sewage | 152 Sewage Blood Serum Fecal Milk | IgG (14.29), IgM (3.57) | ND | RNA (74.07) | 44 |
| China       | NS | Healthy Goats | 225 Tissue | Tissue | ND | RNA (100) | ND |
| China       | NS | Healthy Goats | 196 Tissue | Tissue | ND | RNA (2.6) | ND |
| China       | NS | Healthy Pigs | 120 Blood Serum Liver | IgG (46.7) | ND | RNA (4.0) | ND |
| China       | NS | Cancer Patients | 600 Blood Serum | IgG (39.33) | ND | RNA (4.0) | ND |
| China       | NS | Healthy Individuals | 453 Blood Serum | IgG (39.33) | ND | RNA (4.0) | ND |
| China       | NS | Healthy Individuals | 950 Blood Serum | IgG (22.7), IgM (3.0) | ND | RNA (4.0) | ND |
| China       | NS | Healthy Individuals | 1912 Blood Serum | IgG (66.58), (3.35) IgM (0.84) and Both IgG and IgM | ND | RNA (4.0) | ND |
| China       | NS | HIV patients | 770 Blood Plasma | IgG (44.42), IgM (0.78) and Both IgG and IgM (0.51) | ND | 90 |
Table 3. Continued

| Asian Parts | Region of HEV Occurrence | Study Period | Study Population | Sample Size | Source of Sample | Detection of Anti-HEV Antibodies (%) | Detection of HEV RNA (%) | References |
|-------------|---------------------------|--------------|------------------|-------------|------------------|-------------------------------------|-------------------------|------------|
| China       | Healthy Pigs              | 2017-2018    | Healthy Pigs     | 253         | Bile             | ND                                  | RNA (4.35)              | 49         |
| Hong Kong   | HEV Patients              | 2014-2016    | Lamb            | 24          | Blood Serum      | IgM (100)                           | RNA (75.0)              | 53         |
|             |                           |              | Oysters         | 479         | Meat             | ND                                  | RNA (0)                 |            |
|             |                           |              | Pig             | 479         | Oysters          | ND                                  | RNA (0.2)               |            |
|             |                           |              |                 | 240         | Liver            | ND                                  | RNA (1.5)               |            |
|             |                           |              |                 | 240         | Blood curd       | ND                                  | RNA (0)                 |            |
|             |                           |              |                 | 240         | Intestine        | ND                                  | RNA (0.4)               |            |
| Japan       | Healthy Wild Boars        | 2013-2014    | Meat            | 68          | Blood Serum Liver | IgG/IgM (41.1) ND                  | RNA (10.3)******       | 54         |
|             |                           |              |                 |             | Fecal            |                                     |                         |            |
| Japan       | Patients                  | 2015         | Blood Serum     | 125         | IgG (6.4), IgM (23.2), IgA (17.6) | RNA (23.2)              | 84         |
| Japan       | Healthy Pigs              | 2013-2014    | Oysters         | 480         | Fecal            | ND                                  | RNA (16.25)             | 55         |
| Japan       | Healthy Bats              | 2015         | Pig             | 81          | Fecal            | ND                                  | RNA (3.70)              | 56         |
| Mongolia    | AVH patients              | 2014-2015    | Oysters         | 154         | Blood Serum      | IgG (21.4), IgM (18.8), IgA (20.1)| RNA (20.8)              | 85         |
| South Korea | Rabbits                   | NS           | Blood Serum     | 264         | Fecal            | ND                                  | RNA (6.4)               | 58         |
|             | SPF Rabbits*              | NS           | Blood Serum     | 126         | Fecal            | ND                                  | RNA (6.4)               | 59         |
| South Korea | Rabbits                   | NS           | Blood Serum     | 148         | Fecal            | ND                                  | RNA (13.5)              | 57         |
| Taiwan      | Healthy Chickens          | 2013         | Blood Serum     | 1326        | Fecal            | ND                                  | RNA (20.3)              | 60         |
|             | Healthy Individuals       |              | Anti-HEV (40.57)|            |                  |                                     |                         |            |
|             | AVH patients              |              | IgG (30.0)      |             |                  |                                     |                         |            |
| South       | Bangladesh                | NS           | Blood Serum     | 45          | IgG (31.1)       | ND                                  | RNA (87.5)              | 87         |
| Bangladesh  | February                   | 2011-2014    | Blood Serum     | 48          | IgG (97.9), IgM (94.0), IgA (94.0)| ND                        |                         |            |
|             | AVH patients              |              |                 |             |                  |                                     |                         |            |
| Nepal       | Blood donors              | June-Septem-ber2015 | Blood serum    | 1845        | IgG (41.9), IgM (3.2), IgA (9.5) | ND                        |                         | 66         |
| Nepal       | Blood donors              | Feburary-March2014 | Blood serum    | 581         | IgG (4.6)        | ND                                  |                         | 65         |
| Nepal       | HIV patients              | January-March2015 | Blood serum    | 459         | IgG (39.4), IgM (15.3) | ND                        |                         | 92         |
| Pakistan    | Healthy Pregnant Women    | April-Octo-ber2015 | Blood Serum    | 135         | IgM (15.55)      | ND                                  |                         | 97         |
| India       | AVH patients              | January-March2013 | Blood Serum    | 240         | IgG (76.92)      | ND                                  |                         | 30         |
| India       | AVH patients              | 2015-2016    | Blood Serum     | 95          | IgG (68.42)      | ND                                  | RNA (8.75)              | 41         |
| India       | Pigs Healthy Humans       | NS           | Blood Serum     | 320         | IgG (60.48)      | ND                                  | RNA (0.27)              | 42         |
| India       | Kidney transplant patients | NS           | Blood Serum     | 205         | IgG (25.3), IgM (6.8)| ND                        |                         |            |
| India       | Blood donors              | June-July, 2016, Nov.-Dec. 2016 | Blood Serum    | 1799        | IgG (60.5)      | ND                                  |                         | 28         |
| Southeast   | Cambodia                  | July-Aug. 2014 | Blood donors    | 301         | Blood Serum      | IgG (28.23), IgM (1.0), IgA (41.0)| RNA (0.3)              | 67         |
| Cambodia    | Healthy Pig Professionals | April-June2015 | Blood Serum    | 139         | Blood Serum      | ND                                  |                         | 61         |
Table 3. Continued

| Asian Parts | Region of HEV Occurrence | Study Period | Study Population | Sample Size | Source of Sample | Detection of Anti-HEV Antibodies (%) | Detection of HEV RNA (%) | References |
|-------------|--------------------------|--------------|------------------|-------------|-----------------|-------------------------------------|-------------------------|------------|
| Laos        | March-April 2015          | Slaughter Pigs | 274 Blood Serum  | IgG (54.0) | ND              | ND                                  | ND (0.0)                | 78         |
| Thailand    | March-October 2014        | Healthy Ruminants | 186 Serum Fecal Blood Serum  | Anti-HEV Ab (7.0), IgG (51.8), IgM (17.5) | ND | HEV RNA (8.9) | ND | 79 |
| Thailand    | 2014-2015                 | Healthy Individuals | 721 Blood Serum  | IgG (37.3) | ND | HEV RNA (8.9) | ND | 62 |
| North Russia | NS                        | Pig: Food Items Pig | 2205 Blood Serum Serum  | IgG (5.7), IgM (1.6) | ND | HEV RNA (3.93) | ND | 93 |
| Western Iran | NS                        | Immune Deficient Children | 1273 Blood Serum Blood Serum  | IgG (1.4), IgM (0.25) | ND | HEV RNA (2.3) | ND | 98 |
| Iran        | NS February-July 2014     | ESRD patients Blood donors | 47 Blood Serum Blood Serum  | IgG (10.6), IgG (46.1), IgM (1.4) | ND | HEV RNA (3.9) | ND | 94 |
| Iran        | September-Oct. 2013       | Blood donors | 628 Blood Serum  | IgG (16.7) | ND | HEV RNA (2.3) | ND | 68 |
| Iran        | 2013-2014                 | Thalassemia patients Blood donors | 110 Blood Serum Blood Serum  | IgG (10.0), IgM (1.8) | ND | HEV RNA (2.3) | ND | 69 |
| Iran        | July-Dec. 2014            | Blood donors | 559 Blood Serum  | IgG (8.1) | ND | HEV RNA (2.3) | ND | 95 |
| Iran        | January-March 2014        | Blood donors | 700 Blood Serum  | IgG (6.0), IgM (0.71) | RNA (12.0) | HEV RNA (2.3) | ND | 70 |
| Iran        | 2016-2017                 | Healthy Pregnant Women | 1331 Blood Serum Blood Serum  | IgG (0.83), IgM (0.47) | ND | HEV RNA (2.3) | ND | 99 |
| Isreal      | 2013-2015                 | AVH patients Sewage | 49 Blood Serum Sewage  | ND | RNA (6.1) | HEV RNA (2.3) | ND | 102 |
| Jordan      | 2015-2016                 | Healthy Ruminants Blood donors | 169 Blood Serum Blood Serum  | IgG (30.9) | ND | HEV RNA (8.8) | ND | 80 |
| Qatar       | 2013-2016                 | Blood donors | 5854 Blood Serum  | IgG (20.5), IgM (0.58) | RNA (11.7) | HEV RNA (2.3) | ND | 72 |
| Turkey      | NS                        | Healthy Primary school children | 185 Blood Serum Blood Serum  | IgG (10.6), IgM (0.71) | ND | HEV RNA (2.3) | ND | 81 |
| UAE         | January-July 2013         | Adult Healthy Camels | 203 Fecal Blood Serum  | ND | RNA (1.47) | HEV RNA (2.3) | ND | 63 |

*NS (Not Specified); ND (Not Determined)*

"(Swine, Rabbits, Foxes, Sheep, Sika Deer, Wild Boars, Yaks, Camels, Asiatic Black Bears, African Lion, Red Pandas, Civets, Wolves, Jackals); "Birds(Species not defined); ""Pig stool RNA; """"Rabbit stool RNA; """"Marek’s disease; """"Liver, Lung and Intestine; """"Collective RNA (Liver and Fecal); """"Specific-pathogens free; """"Different sampling site

report from Taiwan, showed the presence of Avian HEV (aHEV) in chickens, and its full genome (6,653 bp) called TWNaHEV demonstrated 98% close connection between the aHEV genotype 4 strains from Hungary. A study conducted in Laos has showed 54.0% (136/252) of the slaughter pigs seropositive for anti-HEV IgG. HEV RNA was reported in the pork and pork items sold in open
air markets in Bangkok, Thailand. A new HEV genotype was observed in camel feces in United Arab Emirates in 2013 and was named as DcHEV (dromedary camel HEV).

### Cases Related to Blood Donors

Transfusion safety is having utmost significance in transfusion services and with time the transfusion safety is enhancing with screening of blood and blood items with regular introduction of better tests. The presence of anti-HEV IgG antibody has generally been taken as proof of prior exposure to HEV. Report from Nepal showed the presence of hepatitis E viremia among the healthy blood donors with a rate of 1.54% and phylogenetic examination of these samples demonstrates the infection with homology of 95% with strain from India and Nepal outbreak in 2014. An investigation conducted to check HEV seroprevalence among the blood donors in Nepal after devastating earthquakes in 2015 showed 3.0% donors positive for anti-HEV IgM, and 2.7% were found with both HEV IgM and IgG antibodies. HEV IgM predominance was related with donors having history of jaundice and pork consumption was found to be a possible risk factor for such infection. Anti-HEV IgG positivity rate was 41.9% and the predominance HEV IgG increased with increasing age and was higher in repeat blood donors, with a history of jaundice and pork consumption. Among the blood donors in Cambodia 28.2% of Anti-HEV IgG were found. One of the isolate belonged to genotype 3 and researcher found a strong genetic link between human transfusion-related HEV-3 strain and one aquatic HEV-3 strain from the different geographical regions in Cambodia. The study suggested that river water, contaminated with HEV-3 by human feces, may be additional source of HEV-3 infection in Cambodia. In another report the blood samples collected from the donors in one of the Iranian city showed 46.1% anti-HEV IgG antibody with noteworthy rate of anti-HEV seroprevalence in subjects in the age group of 61-70 years (90.9%). On the other hand, the amount of anti-HEV IgM was 1.4% and the rate was high among the subjects with 18-30 years of age. A study in the healthy blood donors in Bushehr city, Iran showed that the anti-HEV IgG was 39.1% in the age group 40-60 years and 71.4% in the group older than 60 years: thus indicating that anti-HEV prevalence increased with increase of age. In Tehran, Iran; the HEV seroprevalence was essentially extraordinary with regards to level of education among the healthy blood donors and showed low HEV predominance in university degree holders. A study on the blood donors in Southwest of Iran showed 7.1% of HEV seroprevalence (on the basis of HEV IgG and IgM antibodies), however the HEV RNA from all the isolates revealed 88% to 99% nucleotide sequence similarity with HEV genotype 1. Similarly, 20.7% anti-HEV seroprevalence was found among the blood donors in Qatar amid 2013 and 2016. The high seroprevalence in Qatar may be due to blended population where a substantial extent is originating from hyperendemic nations such as, Egypt and Indian subcontinent.

### Cases Related to General Population

A large number of HEV infection cases were also reported from general population. Serum anti-HEV positive rate was 13.92% in Yunnan region, China. HEV infection rate was 16.13% in male in contrast to females 10.97%, however the highest cases were found among the age group of 20-30 years in both men and women. Farmers exhibited high HEV infection rate (20.35%) and showed that poor health and living condition and regular contact with animals might have caused above phenomenon. In another study a total of 1500 healthy children were screened for the presence of anti-HEV antibodies and out of these 14.93% were found positive for HEV seroprevalence. Blood tests of the workers, in seafood processing plants also revealed the presence of anti-HEV IgG antibody and persons handling the crude seafood had higher anti-HEV IgG (32.54%) than those handling semi-processed items (24.74%). A study conducted in 4 ethnic (Naxi, Bulang, Wa and Hani) population in China detailed the predominance of IgG in Hani, Naxi and Bulang than in Wa ethnic individuals. Univariable analysis showed that HEV IgG pervasiveness was related with origin, gender, education level, smoking habit, body fat ratio and visceral fat index. Study additionally stressed that there might be tendency for eating half-cooked or crude meat and drinking from dairy animals and goat’s crude milk as one of the reason of high HEV IgG in these ethnic people. On the other hand, HEV IgG pervasiveness was most elevated in Hani ethnic group.
as they have the habit of eating raw pork liver and fresh blood from pigs, goats and dogs. An investigation in Dhaka city of Bangladesh had shown 30% cases of HEV among the healthy urban individuals, and has shown relentless increase among persons over 60 years of age. In 18-40 years of age group the prevalence of anti-HEV IgG is nearly double in females than that in males; however, the study did not define the actual causes of HEV in report. Study in Laos villages figured out the higher anti-HEV IgG seropositivity rates among the people who were in close contact with cattle and had 3 times higher probability to be seropositive than members without contact. Consumption of crude animal organs, blood, or risky water was not related with high anti-HEV IgG seropositivity and overall 7.0% of the ruminants had antibodies against HEV, yet this study did not report direct or indirect zoonotic transmission from cattle. In Lop Buri and Narathiwat provinces of Thailand, 37.3% and 8.9% of anti-HEV IgG were found in healthy persons. Majority of residents such as abattoir worker, animal transporters, swine farmers, pork handlers or consumers in Lop Buri who follows Buddhism have no restrictions on consuming pork products and these individuals had the chances to get exposed to HEV. These factors may therefore increases the exposure of HEV in Lop Buri populations, whereas, most Narathiwat residents stick to Islam and were not engaged in any swine related activity and showed less HEV among them. During 2015 and 2016, 30.9% seroprevalence cases of HEV were noticed among the healthy people of Jordan. The study showed that the individuals with formal education had significantly lower HEV seroprevalence as compared to those who had no education.

Interestingly, eating undercooked meat was highly associated with HEV seropositivity. In Denizli province of Turkey, 12.4% Anti-HEV seroprevalence was found among the healthy primary school kids in 2013. Anti-HEV antibodies were found positive in 17 (18.1%) kids of the age group seven-year, and 6 (6.6%) kids of the age group fourteen-year among 185 grade school youngsters. There was no association between the anti-HEV antibody and gender, parental educational level, and socio-economic level, and concluded that insufficient sanitation could be the reason for such prevalence.

**Cases Related to Acute and Chronic Viral Hepatitis Patients**

Acute viral hepatitis is exhibited by symptoms, such as darkened urine, uncolored stool, vomiting, myalgia, weakness and jaundice. Serological markers include high levels of liver transaminases, bilirubin, alkaline phosphatases and β-glutamyltransferase, and detection of anti-HEV IgG/IgM antibodies and HEV-RNA in serum and stool. HEV-4 genotype were found among the acute viral hepatitis (AVH) patients in Shandong province of China and showed that direct contact with pigs, pig farmers; workers in meat handling plant; ingestion of pork, pork items and crude vegetables are essential epidemiological elements that related with HEV infection. An outbreak of HEV in old age nursing home people in Japan showed that some uncooked food items were responsible for such infection. In Mongolia, 20.8% human HEV cases were reported in AVH patients ranging between the years 2014-2015 and 99.8% isolates showed their nucleotide sequence closeness with Nepalese genotype 1. It was presumed that in Mongolia, people with HEV infection or contaminated food came from Nepal.

![Fig. 1. Hepatitis E virus genome. Where, MT= Methyltransferase; Pro= Cysteine protease; PPR= Proline-rich hinge domain Hel= RNA helicase; Pol= RNA-dependent RNA polymerase; X= Macrodomain](image-url)
and other neighboring countries and brought genotype 1 HEV strain. An episode of acute hepatitis E in a hospital of Bangladesh showed 13 patients with history of jaundice although their etiological factors were unknown, but most of the patients shared common drinking water, common cooking and dining facilities and even two persons showed acute hepatitis. Epidemic of HEV occurred in one of the province (Biratnagar) in Nepal in 2014 and >7,000 patients were affected during this epidemic and the epidemic was presumed to be caused by the drinking water. In 2014, water and sewerage pipelines were harmed in various territories of Biratnagar amid development, and, repair of streets and serum tests from 48 AVH patients demonstrated the presence of IgG, IgM and IgA against HEV and all the isolates belonged to genotype 1a. Patient with chronic HEV infection also secreted HEV-RNA and HEV-Ag persistently in urine.

**Cases Related to High Risk Patients**

Hepatitis E virus (HEV) infection was earlier thought to be a self-limiting disease having no risk of chronicity. But recently several chronic cases of hepatitis E have been reported among immunosuppressed patients. Over all rate of HEV among the HIV patients in China were 44.68% and the anti-HEV prevalence expanded by 4.1% every year with patient’s age. Beside age the other factors such as gender, CD4 cell count, WHO stage, marital status and total cholesterol levels are other risk factors that are associated with HEV co-infection in HIV-infected population. Another investigation from China additionally detailed the HEV among disease patients and the rate was 26.0% and the highest HEV seroprevalence occurred in patients with leukemia followed by liver and gastric cancer. This study showed that the HEV seroprevalence was higher in cancer patients than in controls (Healthy people) (26.03% versus 13.0%). The diseased patients are normally immuno-suppressed or immunocompromised, and received blood transfusions, immunosuppressive medications or cancer chemotherapy which prompts their higher vulnerability to HEV. In rural cancer patients the seroprevalence of HEV was 27.8% marginally higher and pigs act as main reservoir of HEV in these areas as compared to urban cancer patients (24.2%). Prevalence of HEV was also examined in the Nepalese HIV
infected patients and in general anti-HEV IgG and anti-HEV IgM similarity was 76.8% and 28.8%, respectively, in HIV-positive patients living in Kathmandu as well as outside Kathmandu. An examination of kids with neurological issues, immune deficient kids and healthy kid’s sera tests in Russia revealed the higher presence of anti-HEV IgG among immune deficient in contrast with healthy kids. Besides this anti-HEV IgM rate was higher (1.1-1.6% versus 0.25%) in immune deficient in contrast with healthy children. This study stressed that immune suppression is a factor of increased risk of infection in children with HEV. Study from Iranian hospital showed the presence of anti-HEV antibody among the patients with end stage renal disease (10.6%), but failed to report any association between HEV, age, gender, duration of hemodialysis (HD), and HCV antibody among the patients. Another study conducted on high risk patients showed 10.0% and 1.8% of anti-HEV IgG and IgM antibodies respectively among the thalassemic patients and the seroprevalence of IgG increased with age, raising from 0% in patients below 10 years to 10% above 10 years of age group. Study emphasized the importance of HEV infection concerning blood multi-transfusion and possibility that the virus could be parenteral exposed or there is another possibility of shared route of transmission.

Cases Related to Pregnancy

In developing countries, the incidence of HEV infection in pregnancy is high and a significant proportion of pregnant women shows mortality rate varying from 30-100% in Israel. However the severe liver injury in pregnant women with Hepatitis E remains unknown. In Pakistan, 15.55% of HEV cases were reported among the pregnant women admitted in various hospitals and none of ladies had jaundice of pregnancy or hepatocellular carcinoma at the time of hospital admission. The study showed that HEV infection increased with repeated exposure of virus, and during pregnancy the severity increases with every trimester and it was more predominant in multigravida ladies and in third trimester, all the babies that were born from infected mothers survived. In Urmia an Iranian city, researchers have reported presence of anti-HEV IgG antibody (3.6%) among the healthy pregnant ladies and none of the subject had history of blood transfusion and tattooing or Hijma. The study did not show any significance between age, pregnancy time, gestational age and income level and concluded that low level of HEV among pregnant ladies may be related with better sanitation, efficient health system and arrangement for safe water than other locales of Iran. Another examination on HEV among the pregnant ladies was conducted in Bushehr the biggest province of Iran and the rate was 6.3%. The Bushehr city is having seaport with a high migration flow, and this may be the solid reason of high seroprevalence of HEV in this city.

Cases Related to Sewage

HEV, which is shed in the feces of infected individuals and animals, has been detected in sewage samples, suggesting that HEV contamination of aquatic environments may also be present. In China 1.32% of HEV was found in sewage plants and BLAST analysis showed 95%-99% nucleotide sequence similarity with swine isolates and belonged to genotype 4. A report from Israel found 8.8% HEV RNA in the sewage water and 6.1% among the hepatitis patients respectively. All of these patients’ and sewage samples sequences belonged to genotype 1 and genotype 3, respectively.

Diagnosis and Vaccine

Various approaches including demonstrative and diagnostic procedures were applied for confirming and collecting information for HEV. Elevated values of liver parameters at routine intervals, including alanine amino-transferase (ALT), aspartate aminotransferase (AST), bilirubin, gamma-glutamyl transpeptidase, and soluble phosphate are delicate yet nonspecific, marker of liver damage. Immune electron microscopy (IEM) identifies infection like particles in fecal samples and, in this method HEV particles were precipitated with native antibody to recover HEV from sera. HEV antigen can be detected in liver tissue utilizing immune fluorescence microscopy in which liver biopsy tissue having HEV particles are absorbed with fluorescent labeled anti-HEV IgG antibody and complex are watched with microscope equipped with epifluorescent gadget. The various approaches used for identification of HEV are shown in figure 2.
sensitivity of the molecular test employed for the detection of HEV RNA. In this way, untraceable viral RNA does not get ruled out from HEV infection. The HEV RNA can be recognized in the beginning of illness and up to 6 months in stool and serum thus, reduces the catch window for HEV. The detection of viral RNA in biological example is the gold standard for identification of acute HEV hepatitis as nucleic acid amplification techniques (NATs) can precisely recognize active infection and help in affirming serological findings. On the other hand, NAT-based identification is a costly methodology that is generally not available at diagnostic research centers, and also it requires exceptionally specialized techniques and trained work force. Over the couple of years, a few NAT tests based on reverse transcription followed by PCR, real-time PCR, and reverse transcription loop-mediated isothermal amplification have been reported for identification and detection of HEV RNA in serum and stool samples. For the detection of four human HEV genotypes, NATs assays have been designed and optimized broadly.

Extraordinary fluctuation has been seen in the execution of in-house tests because of the non-standardized nature of the HEV nucleic acid detection methods. For the detection of hepatitis A, B, and C nucleic acids in sera of infected patients, a single step-multiplex RT-PCR was created in which the conserved regions of all the viral genomes were used as target sequence for amplification and the method was found to be rapid, sensitive, precise and reproducible in nature. The detection limit was found to be 280 copies/ml for hepatitis A virus; for hepatitis B 290 copies/ml; for hepatitis C 30 copies/ml and 300 copies/ml for hepatitis E in a single tube assay system.

A very little knowledge regarding immunological parts of the HEV infection was available until a pattern of antibody response to HEV was recognized and studied. Anti-HEV IgM appears in the acute phase of the HEV infection and is detectable 4 days after the beginning of jaundice and holds on for 5 months. Generally, 90% of patients suffering with acute hepatitis E infection show presence of detectable anti-HEV IgM within 14 days of infection, while anti-HEV IgG antibodies are noticeable soon after the presence of anti-HEV IgM. The way these two classes of antibodies develop at the same time in acute infection makes it hard to build up a precise serological conclusion of acute HEV infection. Therefore, conventional immunoassays for IgM are only effective from 90% to 97%, with false positive aftereffects of up to 2.5% and a few of these results also create false negative outcomes in patients infected with genotype 1 strains. ORF2 and ORF3 antigens and immunodominant peptides are broadly utilized for recognizing IgM, IgG, and IgA antibodies against HEV in commercial HEV serological tests. The cross-serological reactivity of HEV with other viruses acknowledged to causes hepatitis was also additionally researched. Most of the research is engaged to the analysis of acute HEV infection in immunosuppressed patients, for example, AIDS, leukemia and lymphoma and also solid organ transplant beneficiaries. During serological testing those conditions of patients must be considered, where seroconversion to anti-HEV antibodies during infection is delayed or may not occur at all. A quantiferon assay has been developed for the fast result of HEV infection. In this assay, a genotype 3a peptide library (616 overlapping peptides spanning open reading frames [ORFs] 1-3) was used in interferon- gamma (IFN-γ) T-cell ELISpot assay.

Two hepatitis E immunizations have been assessed in clinical preliminaries and the first of these, rHEV5, was produced by GlaxoSmithKline (GSK, Rixensart, Belgium). The other HEV 239 (exchange name Hecolin®), was created by Innovax (Xiamen, China). HEV 239 was authorized in China in 2012 and at present, Hecolin® is accessible in Chinese market and has been affirmed for use in individuals aged more than 16 years. It is used more frequently for inoculating people at high danger of HEV disease, for example, those engaged with creature cultivation, understudies, individuals from the military, sustenance handlers, ladies of childbearing age, and explorers to endemic locales. The Chinese Center for Disease Control and Prevention (CDC) is using an internet framework to gather post-showcasing unfriendly responses/occasions, and has not recognized any worries with the immunization. In spite of the fact that the current 4.5 years of security and adequacy the information for Hecolin® are reassuring, and the information has not yet been gathered in
some areas, including pediatric subjects (< 16 years old), the elderly (> 65 years old), pregnant ladies, people with hidden liver sicknesses or the immunosuppressed individuals. These groups confront a more prominent danger of HEV contamination and are consequently in high need of this vaccine.  

CONCLUSION

It is being observed that the incidence of HEV is gradually expanding and its objective range is not only just developing, but also showing enhancement as well. So, in overall, there is need for improvements in detection of HEV disease and methodologies used for the development of HEV vaccines. Advancement of methods using biosensors for the brisk location of HEV in clinical, sustenance and ecological examples is the need of the hour. The research has been done to develop the amperometric sensor for quickly recognizing Streptococcus pyogenes causing rheumatic heart disease; and ultrasensitive transglutaminase based nano-sensor for early detection of celiac disease in human. Additionally, consideration is required for more proficiency in planning of HEV vaccines development with new innovations to meet the future requirement.

ACKNOWLEDGEMENTS

None

CONFLICT OF INTEREST

The authors declares that there is no conflict of interest.

REFERENCES

1. WHO. 2018. http://www.who.int/features/qa/76/en/. Accessed 30 september, 2018.
2. Hall, G.F. Hepatitis A, B, C, D, E: an update. Ethnicity & Disease, 2007; 17: 52-40-545.
3. Bonino, F., Heermann, K.H., Rizzetto, M., Gerlich, W.H. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. Journal of Virology, 1986; 58(3): 945-950.
4. Khuroo, M.S. Study of an epidemic of non-A, non-B hepatitis: possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. American Journal of Medicine, 1980; 68(6): 818-824.
5. Wong, D., Purcell, R., Sreenivasan, M.A., Prasad, S.R., Pavri, K. Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. The Lancet, 1980; 316(8200): 876-879.
6. Balayan, M.S., Andjaparidze, A.G., Savinskaya, S.S., Ketladeze, E.S., Braginsky, D.M., Savinov, A.P, Poleschuk, V.F. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Interivirology, 1983; 20(1): 23-31.
7. Reyes, G.R., Purdy, M.A., Kim, J.P., Luk, K.C., Young, L.M., Fry, K.E., Bradley, D.W. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science, 1990; 247(4948): 1335-1339.
8. Yamashita, T., Mori, Y., Miyazaki, N., Cheng, R.H., Yoshimura, M., Unno, H., Shima, R., Morishki, K., Tsukihara, T., Li, T.C., Takeda, N. Biological and immunological chara-cteristics of hepatitis E virus-like particles based on the crystal structure. Proceedings of National Academy of Sciences, 2009; 106(31): 12986-12991.
9. Tam, A.W., Smith, M.M., Guerra, M.E., Huang, C.C., Bradley, D.W., Fry, K.E., Reyes, G.R. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology, 1991; 185(1): 120-131.
10. Koonin, E.V., Gorbalenya, A.E., Purdy, M.A., Rozanov, M.N., Reyes, G.R., Bradley, D.W. Computer-assisted assignment of func-tional domains in the nonstructural polyprotein of hepatitis E virus: deli-neation of an additional group of positive-strand RNA plant and animal viruses. Proceedings of National Academy of Sciences, 1992; 89(17): 8259-8263.
11. Li, T.C., Yamaakwa, Y., Suzuki, K., Tatsumi, M., Razak, M.A., Uchida, T., Takeda, N., Miyamura, T. Expression and self-assembly of empty virus-like particles of hepatitis E virus. Journal of Virology, 1997; 71(10): 7207-7213.
12. He, S., Miao, J., Zheng, Z., Wu, T., Xie, M., Tang, M., Zhang, J., Ng, M.H., Xia, N. Putative receptor-binding sites of hepatitis E virus. Journal of General Virology, 2008; 89(1): 245-249.
13. Kalia, M., Chandra, V., Rahman, S.A., Sehgal, D., Jameel, S. Heparan sulfate prote-oglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. Journal of Virology, 2009; 83(24): 12714-12724.
14. Xing, L., Wang, J.C., Li, T.C., Yasutomi, Y., Lara, J., Khudyakov, Y., Schofield, D., Emerson, S.U., Purcell, R.H., Takeda, N., Miyamura, T. Spatial configuration of hepatitis E virus antigenic domain. Journal of Virology, 2011; 85(2): 1117-11124.
15. Guu, T.S., Liu, Z., Ye, Q., Mata, D.A., Li, K., Yin, C., Zhang, J., Tao, Y.J. Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proceedings of National Academy of Sciences, 2009; 106(31): 12992-12997.
16. Tang, X., Yang, C., Gu, Y., Song, C., Zhang, X., Wang, Y., Zhang, J., Hew, C.L., Li, S., Xia, N., Sivaraman, J. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proceedings of National Academy of Sciences, 2011; 108(25): 10266-10271.
17. Xing, L., Li, T.C., Mayazaki, N., Simon, M.N., Wall, J.S., Moore, M., Wang, C.Y., Takeda, N., Wakita, T., Miyamura, T., Cheng, R.H. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. Journal of Biological Chemistry, 2010; 285(43): 33175-33183.
18. Meng, J., Dai, X., Chang, J.C., Lopareva, E., Pillot,
Arankalle, V.A., Paranjape, S., Emerson, S.U., Purcell, S.U., Graff, J., Torian, U., Nguyen, H., Emerson, S.U. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. Journal of General Virology, 2009; 90(8): 1880-1891.

Graff, J., Torian, U., Nguyen, H., Emerson, S.U. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. Journal of Virology, 2010; 84(18): 9059-9069.

Yamada, K., Takahashi, M., Hoshino, Y., Takahashi, H., Ichiyama, K., Nagashima, S., Tanaka, T., Okamoto, H. ORF3 protein of hepatitis E virus is essential for virion release from infected cells. Journal of General Virology, 2009; 90(8): 1880-1891.

Emerson, S.U., Nguyen, H.T., Torian, U., Burke, D., Engle, R., Purcell, R.H. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. Journal of Virology, 2010; 84(18): 9059-9069.

Huang, F.F., Sun, Z.F., Emerson, S.U., Purcell, R.H., Ichiyama, K., Nagashima, S., Tanaka, T., Okamoto, H. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. Journal of Virology, 2010; 84(18): 9059-9069.
45. Li, W., Guan, D., Su, J., Takeda, N., Wakita, T., Li, T.C., Ke, C.W. High prevalence of rat hepatitis E virus in wild rats in China. *Veterinary Microbiology*, 2013; 165(3-4): 275-280.

46. Xia, J., Zeng, H., Liu, L., Zhang, Y., Liu, P., Geng, J., Wang, L., Wang, J., Zhang. Swine and rabbits are the main reservoirs of hepatitis E virus in China: detection of HEV RNA in feces of farmed and wild animals. *Archives of Virology*, 2015; 160(11): 2791-2798.

47. Yang, S., Wang, L., Sun, S. Natural infection with avian hepatitis E virus and Marek's disease virus in brown layer chickens in China. *Avian Disease*, 2016; 60(3): 698-704.

48. Zhang, L., Li, K., Huang, S., Liu, D., Rehman, M.U., Lan, Y., Zhang, H., Wang, L., Hao, Y., Iqbal, M.K., Mehmood, K. Seroprevalence and risk factors associated with hepatitis E virus infections among people and pigs in Tibet, China. *Acta Tropica*, 2017; 172: 102-106.

49. Zhang, L., Huang, S., Li, K., Rehman, M.U., Jiang, X., Rehman, M.U., Wang, L., Zhuang, H. Swine and rabbits are the main reservoirs of hepatitis E virus in China: detection of HEV RNA in feces of farmed and wild animals. *Veterinary Microbiology*, 2017; 205: 158-164.

50. Long, F., Yu, W., Yang, C., Wang, J., Li, Y., Li, Y., Huang F. High prevalence of hepatitis E virus infection in goats. *Journal of Medical Virology*, 2017; 89: 1981-1987.

51. Li, S., Liu, M., Cong, J., Zhou, Y., Miao, Z. Detection and characterization of hepatitis E virus in goats at slaughter-house in Tai’an Region, China. *BioMed Research International*, 2017; 1-5.

52. Wu, J., Si, F., Jiang, C., Li, T., Jin, M. Molecular detection of hepatitis E virus in sheep from southern Xinjiang, China. *Virus Genes*, 2015; 50(3): 410-417.

53. Chan, M.C., Kwok, K., Hung, T.N., Chan, P.K. Molecular epidemiology and strain comparison between hepatitis E virus in human sera and pig livers during 2014-2016 in Hong Kong. *Journal of Clinical Microbiology*, 2017; 55: 1408-1415.

54. Mototya, T., Nagata, N., Komori, H., Doi, I., Kurosawa, M., Keta, T., Sasaki, N., Ishii, K. The high prevalence of hepatitis E virus infection in wild boars in Ibaraki Prefecture, Japan. *Journal of Veterinary Medical Science*, 2015; 77(12): 1705-1709.

55. Sasaki, Y., Haruna, M., Uema, M., Noda, M., Yamada, Y. Prevalence and phylogenetic analysis of hepatitis E virus among pigs in Japan. *Japanese Journal of Infectious Diseases*, 2018; 71(1): 75-78.

56. Kobayashi, T., Murakami, S., Yamamoto, T., Mineshita, K., Sakuyama, M., Sasaki, R., Maeda, K., Horimoto, T. Detection of bat hepatitis E virus RNA in microbats in Japan. *Virus Genes*, 2018; 54: 599-602.

57. Kim, Y.H., Park, B.J., Ahn, H.S., Han, S.H., Go, H.J., Kim, D.H., Lee, J.B., Park, S.Y., Song, C.S., Lee, S.W., Choi, I.S. Evidence of hepatitis E virus infection in specific pathogen-free rabbits in Korea. *Virus Genes*, 2018; 54: 587-590.

58. Hsu, L.W.Y., Tsai, H.J. Avian hepatitis E virus in chickens, Taiwan, 2013. *Emerging Infectious Diseases*, 2014; 20(1): 149-151.

59. Khounsivith, V., Tritz, S., Khenkha, L., Phoutana, V., Keosengthong, A., Pomma-sichan S., Nouanthong, P., H bschen, J.M., Snoeck, C.J., Reinharz, D., Muller, C.P. High circulation of Hepatitis E virus in pigs and professionals exposed to pigs in Laos. *Zoonoses and Public Health*, 2018; 65(8): 1020-1026.

60. Intharasongkroh, D., Sa-nguanmoo, P., Thuanthap, S., Thongmee, T., Duang-in, A., Klinflueng, S., Chansanerong, J., Vongpunsawad, S., Theamboonlers, A., Payungporn, S., Chirathaworn, C. Hepatitis E virus in pork and variety meats sold in fresh markets. *Food and Environmental Virology*, 2017; 9(1): 45-53.

61. Shrestha, A.C., Flower, R.L., Seed, C.R., Rajkarnikar, R., Hok, K., Pavio, N., Rouet, F. Hepatitis E virus prevalence among blood donors in Nepal. *Hepatitis Research and Treatment*, 2016; 2016: 1-8.

62. Shrestha, A., Adhikari, A., Shrestha, A., Rauniyar, R., Sapkota, B., Shrestha, S., Shrestha, S., Gupta, P.P., Manandhar, K.D. First report of hepatitis E virus viremia in healthy blood donors from Nepal. *VirusDisease*, 2016; 27(3): 324-326.

63. Gupta, B.P., Pillai, T.K., Shrestha, A., Rauniyar, R., Sapkota, B., Shrestha, S., Gupta, P.P., Manandhar, K.D. First report of hepatitis E virus viremia in healthy blood donors from Nepal. *BMC Infectious Diseases*, 2016; 16(1): 707.

64. Nouhin, J., Prak, S., Madec, Y., Barennes, H., Weissel, R., Hok, K., Pavio, N., Rouet, F. Hepatitis E virus antibody prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia). *Transfusion*, 2016; 56(10): 2597-2601.

65. Farshadpour, F., Taherkhani, R., Makvandi, M. Prevalence of hepatitis E virus among adults in southwest of Iran. *Hepatitis Research and Treatment*, 2015; 1-5.

66. Naeimi, B., Kalimani, F.M., Pourfatolah, A.A., Nikouyan, N., Okhovat, M.A., Naderi, S. Detection of hepatitis E virus and hepatitis A virus and hepatitis E virus seroprevalence among blood donors in Tehran, Iran. *Hepatitis Monthly*, 2015; 15(11): e92219.

67. Semakurwi, A., Shara, R., Keyhani, H., Alavian, S.M., Shabanakhae, A.N.T., Olyaie, R.S., Keshvari, M. Hepatitis A virus and hepatitis E virus seroprevalence among blood donors in Iran. *Hepatitis Monthly*, 2016; 16(1): e32215.

68. Parsa, R., Adibzadeh, S., Behbahani, A.B., Farhadi, A., Yaghobi, R., Dehbidi, G.R.R., Hajizamani, S., Rahbar, S., Nikouyani, N., Ohkohet, M.A., Naderi, S. Detection of hepatitis E virus genotype 1 among blood donors from Southwest of Iran. *Hepatitis Monthly*, 2016; 16(6): e34202.
72. Nasrallah, G.K., Al-Abi, E.S., Ghandour, R., Ali, N.H., Taleb, S., Hedaya, L., Ali, F., Huwaidy, M., Husseini, A. Seroprevalence of hepatitis E virus among blood donors in Qatar (2013-2016). Transfusion, 2017; 57(7): 1801-1807.

73. Li, J.J., Shen, Y.Y., Ai, Z.Q., Guo, L., Geng, C.R. Seroepidemiology and genetic chara-cterization of hepatitis E virus in western Yunnan Province. Asian Pacific Journal of Tropical Medicine, 2014; 7(11): 909-912.

74. Meng, Q.F., You, H.L., Wang, W.L., Zhou, N., Dong, W., Cong, W. Seroprevalence and risk factors of hepatitis E virus infection among children in China. Journal of Medical Virology, 2015; 87(9): 1573-1577.

75. Cui, W., Sun, Y., Xu, A., Gao, R., Gong, L., Zhang, L., Jiang, M. Hepatitis E seroprevalence and related risk factors among seafood processing workers: A cross-sectional survey in Shandong Province, China. International Journal of Infectious Disease, 2016; 49: 62-66.

76. Feng, Y., Feng, Y.M., Wang, S., Xu, F., Zhang, X., Zhang, C., Jia, Y., Yang, W., Xie, X., Yin, J. High seroprevalence of hepatitis E virus in the ethnic minority populations in Yunnan, China. PloS One, 2018; 13(5): e0197577.

77. Rahman, S., Mamun-Al-Mahtab, M.J., Tabassum, S., Akbar, S.M.F. Epidemiology of Hepatitis E Virus in an urban community in dhaka city. EuroAsian Journal of Hepatogastroenterology, 2014; 4(1): 4-6.

78. Tritz, S.E., Khounvisith, V., Pommasichan, S., Cadranel, J.F., Pavio, N., Renou, C., Lafeuillade, A., Cadranel, J.F., Pavio, N., Renou, C., Lafeuillade, A. Hepatitis E virus in HIV-infected patients. AIDS, 2010; 24: 1493-1499.

79. Shrestha, A., Adhikari, A., Bhattachari, R., Rauniyar, R., Debes, J.D., Boonstra, A., Lama, T.K., Al-Mahtab, M., Butt, A.S., Akbar, S.M.F., Aryal, N. Seroprevalence and risk of hepatitis E virus infection in the HIV population of Nepal. Virology Journal, 2017; 14(1): 228.

80. Shrestha, A., Shrestha, A., Adhikari, A., Bhattachari, R., Rauniyar, R., Debes, J.D., Boonstra, A., Lama, T.K., Al-Mahtab, M. Hepatitis E virus infection in cancer patients in eastern China. International Journal of Infectious Diseases, 2018; 7: 42-47.

81. Mousavi, S.B., Motemednia, F., Mousavi, M.B. Epidemiology of hepatitis E virus infection in patients on chronic hemo-dialysis. Jundishapur Journal of Microbiology, 2014; 7(5): e6999.

82. Jahromi, A.S., Ahmadi-vasmehjani, A., Zabetian, H., Potemkin, I.A., Lopatukhina, M.A., Prokhorova, E.L., Dzhivareva, A., Isayev, O.A., Kozhanova, T.V., Ivanova, O.E., Silenova, O.V., Setdlkova, N., Nyamkhuu, D., Okamoto, H. Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis in Mongolia: The first report of the full genome sequence of a novel genotype 1 hepatitis E virus strain. Journal of Medical Virology, 2018; 90(1): 84-92.

83. Rahman, S., Mamun-Al-Mahtab, M.J., Tabassum, S., Akbar, S.M.F. Epidemiology of Hepatitis E Virus in an urban community in dhaka city. EuroAsian Journal of Hepatogastroenterology, 2014; 4(1): 4-6.

84. Shrestha, A., Shrestha, A., Adhikari, A., Bhattachari, R., Rauniyar, R., Debes, J.D., Boonstra, A., Lama, T.K., Al-Mahtab, M. Hepatitis E virus infection in cancer patients in eastern China. International Journal of Infectious Diseases, 2018; 7: 42-47.

85. Mousavi, S.B., Motemednia, F., Mousavi, M.B. Epidemiology of hepatitis E virus infection in patients on chronic hemo-dialysis. Jundishapur Journal of Microbiology, 2014; 7(5): e6999.
outcomes. *East Mediterranean Health Journal*, 2017; 23(8): 559-563.

98. Khameneh, Z.R., Sepehrvand, N., Khalkhali, H.R. Seroprevalence of hepatitis E among pregnant women in Urmia, Iran. *Hepatitis Monthly*, 2013; 13(11): e10931.

99. Farshadpour, F., Taherkhani, R., Ravanbod, M.R., Eghbali, S.S., Taherkhani, S., Mahdavi, E. Prevalence, risk factors and molecular evaluation of hepatitis E virus infection among pregnant women resident in the northern shores of Persian Gulf, Iran. *PloS One*, 2018; 13(1): e0191090.

100. La Rosa, G., Pourshaban, M., Laconelli, M., Vennarucci, V.S., Muscillo, M. Molecular detection of Hepatitis E virus in sewage samples. *Applied Environmental Microbiology*, 2010; 76(17): 5870-5873.

101. Li, H., Li, W., She, R., Yu, L., Wu, Q., Yang, J., Hu, F., Soomro, M.H., Shi, R., Hao, W., Zhao, Y. Hepatitis E virus genotype 4 sequences detected in sewage from treatment plants of China. *Food and Environmental Virolology*, 2017; 9(2): 230-233.

102. Ram, D., Manor, Y., Gozlan, Y., Schwartz, E., Ben-Ari, Z., Mendelson, E., Mor, O. Hepatitis E virus genotype 3 in sewage and genotype 1 in acute hepatitis cases, Israel. *American Journal of Tropical Medicine and Hygiene*, 2016; 95(1): 216-220.

103. Aggarwal, R., Jameel, S. Hepatitis E. *Hepatitis Monthly*, 2011; 54(6): 2218-2226.

104. Dienstag, J.L., Alling, D.W., Purcell, R.H. Quantitation of antibody to hepatitis A antigen by Immune Electron Microscopy. *Infection and Immunity*, 1976; 13(4): 1209-1213.

105. Krawczynski, K., Bradley, D.W. Enterically transmitted non-A, non-B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques. *Journal of Infectious Diseases*, 1989; 159(6): 1042-1049.

106. Colson, P., Coze, C., Gallian, P., Henry, M., De Micco, P., Tamalet, C. Transfusion-associated hepatitis E, France. *Emerging Infectious Diseases*, 2007; 13(4): 648-649.

107. Sarin, S.K., Kumar, M. Hepatitis E: In: Boyer, T., Manns, M., Wright, T.L. Hepatology: A Textbook of Liver Disease, pp. 693-724. 5th Ed. Philadelphia, PA: Saunders, 2006.

108. Huang, S., Zhang, X., Jiang, H., Yan, Q., Ai, X., Wang, Y., Cai, J., Jiang, L., Wu, T., Wang, Z., Guan, L. Profile of acute infectious markers in sporadic hepatitis E. *PloS One*, 2010; 5(10): e13560.

109. Mirazo, S., Ramos, N., Mainardi, V., Gerona, S., Arbiza, J. Transmission, diagnosis, and management of hepatitis E: an update. *Hepatic Medicine Evidence and Research*, 2014; 6: 45-59.

110. Lan, X., Yang, B., Li, B.Y., Yin, X.P., Li, X.R., Liu, J.X. Reverse transcription-in-loop-mediated isothermal amplification assay for rapid detection of hepatitis E virus. *Journal of Clinical Microbiology*, 2009; 47(7): 2304–2306.

111. Jothikumar, N., Cromeans, T.L., Robertson, B.H., Meng, X.J., Hill, V.R. A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. *Journal of Virological Methods*, 2006; 131(1): 65–71.

112. Gyarmati, P., Mohammed, N., Norder, H., Blomberg, J., Belsk, S., Widén, F. Universal detection of hepatitis E virus by two real-time PCR assays: TaqMan and Primer-Probe Energy Transfer. *Journal of Virological Methods*, 2007; 146(1-2): 226–235.

113. Baylis, S.A., Henschke, K.M., Belfield, C.M. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique (NAT)-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory. *Journal of Clinical Microbiology*, 2011; 49(4): 1234-1239.

114. Irshad, M., Ansari, M.A., Irshad, K., Lingaiah, R. Novel singletype multiplex real-time polymerase chain reaction assay for simultaneous quantification of hepatitis virus A, B, C, and E in serum. *Journal of Gastroenterology and Hepatology*, 2013; 28(12): 1869-1876.

115. Favors, M.O., Fields, H.A., Purdy, M.A., Yashina, T.L., Aleksandrov, A.G., Alter, M.J., Yarasheva, D.M., Bradley, D.W., Margolis, H.S. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. *Journal of Medical Virolology*, 1992; 36(4): 246-250.

116. Legrand-Abravanel, F., Thevenet, J., Mansuy, J.M., Saune, K., Vischi, F., Peron, J.M., Kumar, N., Rostaing, L., Izopet, J. Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. *Clinical and Vaccine Immunology*, 2009; 16(5): 772-774.

117. Drobenic, J., Meng, J., Reuter, G., Greene-Montfort, T., Khudyakova, N., Dimitrova, Z., Kamili, S., Teo, C.G. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangentotypic evaluation of performances. *Clinical Infectious Diseases*, 2010; 51(3): e24-27.

118. Herremans, M., Bakker, J., Duizer, E., Vennema, H., Koopmans, M.P. Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 in infections in a setting of low endemicity. *Clinical and Vaccine Immunology*, 2007; 14(5): 562–568.

119. Takahashi, M., Kusakai, S., Mizuo, H., Suzuki, K., Fujimura, K., Masuko, K., Sugai, Y., Aikawa, T., Nishizawa, T., Okamoto, H. Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) is highly specific for diagnosis of acute HEV infection. *Journal of Clinical Microbiology*, 2005; 43(1): 49-56.

120. Zhang, S., Tian, D., Zhang, Z., Xiong, J., Yuan, Q., Ge, S., Jiang, J., Xia, N. Clinical significance of anti-HEV IgA in diagnosis of acute genotype 4 hepatitis E virus infection negative for anti-HEV IgM. *Diseases and Sciences*, 2009; 54(11): 2512-2518.
Hepatology, 2016; 64(6): 1934-1950.

123. Li, S.W., Zhao, Q., Wu, T., Chen, S., Zhang, J., Xia, N.S. The development of a recombinant hepatitis E vaccine HEV 239. *Human Vaccines and Immunotherapeutics*, 2015; 11(4): 908-914.

124. Zhang, J., Liu, C.B., Li, R.C., Li, Y.M., Zheng, Y.J., Li, Y.P., Luo, D., Pan, B.B., Nong, Y., Ge, S.X., Xiong, J.H. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. *Vaccine*, 2009; 27(12): 1869-1874.

125. Zhu, F.C., Zhang, J., Zhang, X.F., Zhou, C., Wang, Z.Z., Huang, S.J., Wang, H., Yang, C.L., Jiang, H.M., Cai, J.P., Wang, Y.J. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *The Lancet*, 2010; 376(9744): 895-902.

126. Wu, T., Li, S.W., Zhang, J., Ng, M.H., Xia, N.S., Zhao, Q. Hepatitis E vaccine development: a 14-year odyssey. *Human Vaccines and Immunotherapeutics*, 2012; 8(6): 823-827.

127. Kaushal, A., Singh, S., Kumar, A., Kumar, D. Nano-Au/cMWCNT modified speB gene specific amperometric sensor for rapidly detecting Streptococcus pyogenes causing rheumatic heart disease. *Indian Journal of Microbiology*, 2017; 57(1): 112-124.

128. Gupta, S., Kaushal, A., Kumar, A., Kumar, D. Ultrasensitive transglutaminase based nanosensor for early detection of celiac disease in human. *International Journal of Biological Macromolecules*, 2017; 5: 905-911.

129. Kamar, N., Dalton, H.R., Abravanel, F., Izopet, J. Hepatitis E virus infection. *Clinical Microbiology Reviews*, 2014; 27(1): 116-138.

130. Parashar, D., Khalkar, P., Arankalle, V.A. Survival of hepatitis A and E viruses in soil samples. *Clinical Microbiology and Infection*, 2011; 17(11): E1-E4.

131. Aggarwal, R. Hepatitis E: clinical presentation in disease-endemic areas and diagnosis. *Seminars in Liver Disease*, 2013; 33(1): 30-40.

132. Fujiwara, S., Yokokawa, Y., Morino, K., Hayasaka, K., Kawabata, M., Shimizu, T. Chronic hepatitis E: a review of the literature. *Journal of Viral Hepatitis*, 2014; 21(2): 78-89.

133. Khuroo, M.S., Khuroo, M.S., Khuroo, N.S. Hepatitis E: discovery, global impact, control and cure. *World Journal of Gastroenterology*, 2016; 22(31): 7030-7045.